We recently published a list of 8 Most Undervalued Growth Stocks To Buy According To Wall Street Analysts. In this article, we are going to take a look at where Jazz Pharmaceuticals plc (NASDAQ:JAZZ) stands against other undervalued growth stocks according to wall street analysts.
Will There Be Another 50 Basis Point Cut Considering the Jobs Report?
Analysts and the market blamed the Fed for not cutting the interest rate earlier in July. However, the sentiments seemed to have shifted with the recent jobs report with above-expectation data. The data from the Job market shows that Nonfarm payrolls increased by 254,000 in September and unemployment rates fell to 4.1% from 4.2%.
These new statistics are making the market think, was the 50 basis point too much another question that comes up is what the Fed will do in the next meeting. Sylvia Jablonski, Defiance ETFs CEO and CIO joined CNBC to talk about the issue recently. She mentioned that Fed is data dependent and every move they make is based on the latest available data. The market was questioning the Fed for the delay in rate cuts, however, the data that the Fed had at the time was pointing towards the job market going the other way. Jablonski thinks that they made the right call to cut the interest rates by 50 basis points. However, with the current jobs market report it is difficult to expect another 50 basis point cut. She thinks that it will either be by a 25 basis point cut or no cut at all.
As of now the market seems to be doing good, the job numbers came in above expectations, and wages are good which tells that the consumers are likely to spend more which will be feasible for the economy. Jablonski also mentioned that the S&P 500 has been up by 20% in 2024 and thinks that the earnings for stocks are strong.
The analysis pointed out by Jablonski and many other analysts currently is pointing towards a soft landing scenario becoming more and more feasible. This becomes particularly important for the growth stocks. Historically speaking value stocks have outperformed growth stocks, however, this has not been the case for the past 10 years. Moreover, according to Ben Snider, growth stocks tend to perform better in a slowing economy with the Federal Reserve cutting rates.
One of the key points to note here is that analysts are suggesting diversifying the portfolio, to look beyond technology stocks and quality growth stocks that have good earnings and prospects of sustained growth. We covered Ben Snider’s interview in 7 Unstoppable Growth Stocks To Buy Now. Here’s a piece from the article:
“On August 15, Ben Snider from Goldman Sachs appeared in a CNBC interview and mentioned that he still prefers growth stocks over value stocks but emphasized diversified portfolios. He pointed out that the base case is not the economy running into recession, it is quite the opposite as the data suggests. Ben Snider believes that the economy continues to grow and backed his arguments by mentioning the second quarter earnings season growth, the S&P 500 growth, and the Federal Reserve rate cuts. Therefore the base case as per Snider is higher equity prices by the year end.
While elaborating on his statement about growth stocks, Ben Snider pointed out that an environment of slowing but healthy economic growth along with falling interest rates have historically supported growth stocks over value stocks.
Most importantly, Snider emphasized that there is a risk for some extremely large stocks both from a positioning point of view and from their inability to maintain very strong rates of growth. In addition, the AI bubble problem along with very high analyst expectations have priced these stocks to an extremely overvalued situation.
The solution, as presented by Snider, is to adopt a more diversified approach and go for a selection of smaller tech stocks along with other high-growth industries. Some of the major growth industries mentioned during the interview were smaller tech stocks, the healthcare industry, and some other European stocks that are on the verge of cutting-edge innovation.”
What are the Broader Implications for Tech Stocks?
The technology sector is one of the main contenders when it comes to growth stocks. Ray Wang, principal analyst and founder of Constellation Research, appeared on CNBC to talk about the broader implications for tech stocks. Wang noted that Wall Street’s favorite chip maker is “priced for perfection”. He anticipates strong earnings due to widespread investments in AI and data center chips across the tech sector. A significant point raised by Wang was the trend of reallocating cybersecurity budgets to fund AI initiatives. Wang suggested that companies believe enhancing AI capabilities could improve their cybersecurity resilience, although this approach carries risks if a major cybersecurity breach occurs.
Wang has stakes in all seven companies in the Magnificent Seven and believes they represent a solid investment thesis amid falling interest rates. He also acknowledged that many analysts believe that falling interest rates are more favorable for other stocks excluding the Magnificent Seven, however, he thinks that big tech stocks are safer and better positioned for growth in the current climate situation.
Wang also made an interesting comparison between the historic time of the internet boom and today’s AI and data center revolution. He highlighted that unlike the decentralized nature of the internet era, today’s tech landscape is more centralized, with fewer dominant players. Thereby indicating that there will be fewer winners with more gains in the tech sector.
Our Methodology
To compile a list of the 8 most undervalued growth stocks to buy according to Wall Street analysts, we used the Finviz stock screener and CNN. Using the screener, we sifted through high-growth industries including Technology, Biotechnology, Renewable Energy, and more to get an aggregated list of 20 undervalued growth stocks.
Our criteria to call a stock cheap/undervalued is as follows: Forward P/E below the market average i.e. 24.35 (as per the Wall Street Journal) and earnings growth positive for the current year, both sourced from Yahoo Finance.
Once we had the list of undervalued growth stocks, we then ranked these stocks based on the analyst upside potential sourced from CNN. The list is ranked in ascending order of the analyst upside potential. Moreover, please note that the indicators used in the article were recorded on October 7th, 2024.
Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A biopharmaceutical scientist in their lab, studying a newly-diagnosed therapy-related acute myeloid leukemia. .
Jazz Pharmaceuticals plc (NASDAQ:JAZZ)
Forward P/E: 5.6
Earnings Growth: 7.00%
Number of Hedge Fund Holders: 44
Analyst Upside Potential: 59.99%
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is the most undervalued growth stock to buy according to Wall Street analysts. 19 analysts have a strong Buy rating for the stock with their median price target representing a 60% upside from the current levels.
It is a biopharmaceutical company that focuses on developing treatments for neurological diseases and oncology. While the company already has a portfolio of top-performing medicines in the related fields, it recently got good news from the FDA. The FDA granted priority review for Zanidatamab, which is said to hit the market in around 2 months.
As of now, Xywav, Epidiolex/Epidyolex, and Rylaze/Enrylaze are fueling growth and driving the company’s revenue. The three medicines combined led the total revenue to grow 15% year-over-year during the second quarter of 2024. Moreover, the oncology department of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was also not behind with a 10% increase during the same time.
The company has an already existing portfolio of more than 9 FDA-approved products curing patients with neurological disorders and in the oncology department. Not only this, it is constantly researching and lining up its pipeline for further approvals making it well-positioned for future growth.
Aristotle Capital Global Equity Strategy made the following comment about Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in its Q3 2023 investor letter:
“During the quarter, we sold our position in Magna International and invested in a new position, Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Founded in 2003, Jazz Pharmaceuticals is a global biopharmaceutical company headquartered in Ireland. The drugmaker’s portfolio of nine approved products focuses on conditions with limited therapeutic treatments in neuroscience (~75% of 2022 revenue) and oncology (~25%).
Jazz’s drug Xyrem was added to its portfolio in 2005 and was approved for use in patients with narcolepsy. The drug’s strong efficacy propelled it to be the standard of care for this incurable sleep condition and has achieved wide adoption for the treatment of excessive daytime sleepiness and cataplexy (episodes of loss of muscle control).
Xyrem’s patent exclusivity ended in January 2023, and authorized generic versions of the product have entered the market. To prepare for the patent cliff, the company developed Xywav, a lower‐sodium version of Xyrem, which is touted for its potentially better heart safety. The drug has received FDA approval for the treatment of narcolepsy and idiopathic hypersomnia and has orphan drug exclusivity through 2027…” (Click here to read the full text)
Overall, JAZZ ranks 1st on our list of Most Undervalued Growth Stocks To Buy According To Wall Street Analysts. While we acknowledge the potential of JAZZ as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for a promising AI stock that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’.
Disclosure: None. This article is originally published at Insider Monkey.